Pre-stroke use of antihypertensives, antiplatelets, or statins and early ischemic stroke outcomes

Cerebrovascular Diseases

Volumn 27, Issue 4, 2009, Pages 398-402

  Yu, A Y X ^a   Keezer, M R ^a   Zhu, Bin ^a   Wolfson, Christina ^a   Côté, Robert ^a,b  

^a MCGILL UNIVERSITY   (Canada)

^b MONTREAL GENERAL HOSPITAL   (Canada)

Author keywords

Acute ischemic stroke; Acute stroke outcome; Antihypertensive therapy; Antiplatelet therapy; Clinical outcome; Statins

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CENTRAL MUSCLE RELAXANT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE DONOR;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; DRUG USE; FEMALE; HEART ATRIUM FIBRILLATION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADRENERGIC BETA-ANTAGONISTS; AGED; AGED, 80 AND OVER; ANGIOTENSIN II; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PROGNOSIS; QUEBEC; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; STROKE;

EID: 61649086176     PISSN: 10159770     EISSN: None     Source Type: Journal    
DOI: 10.1159/000207444     Document Type: Article

References (33)

1. Sacco RL, Adams R, Albers G, et al: Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke. Stroke 2006; 37: 577-617.
2. Ovbiagele B, Kidwell CS, Starkman S, et al: Angiotensin 2 type 2 receptor activity and ischemic stroke severity. Neurology 2005; 65: 851-854.
3. Kumar S, Savitz S, Schlaug G, Caplan L, Selim M: Antiplatelets, ACE inhibitors, and statins combination reduces stroke severity and tissue at risk. Neurology 2006; 66: 1153-1158.
4. Sanossian N, Saver JL, Rajajee V, et al: Premorbid antiplatelet use and ischemic stroke outcomes. Neurology 2006; 66: 319-323.
5. Greisenegger S, M̈llner M, Tentschert S, Lang W, Lalouschek W: Effect of pretreatment with statins on the severity of acute ischemic cerebrovascular events. J Neurol Sci 2004; 221: 5-10.
6. Reeves MJ, Gargano JW, Luo Z, Mullard AJ, Jacobs BS, Majid A: Effect of pretreatment with statins on ischemic stroke outcomes. Stroke 2008; 39: 1779-1785.
7. Selim M, Savitz S, Linfante I, Caplan L, Schlaug G: Effect of pre-stroke use of ACE inhibitors on ischemic stroke severity. BMC Neurology 2005; 5: 10.
8. Ricci S, Lewis S, Sandercock P: Previous use of aspirin and baseline stroke severity: an analysis of 17,850 patients in the International Stroke Trial. Stroke 2006; 37: 1737-1740.
9. Moonis M, Kane K, Schwiderski U, Sandage BW, Fisher M: HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke 2005; 36: 1298-1300.
10. Jonsson N, Asplund K: Does pretreatment with statins improve clinical outcome after stroke? Stroke 2001; 32: 1112-1115.
11. Mart́-F̀bregas J, Gomis M, Arboix A, et al: Favorable outcome of ischemic stroke in patients pretreated with statins. Stroke 2004; 35: 1117-1123.
12. Elkind MSV, Flint ACF, Sciacca RR, Sacco RL: Lipid-lowering agent use at ischemic stroke onset is associated with decreased mortality. Neurology 2005; 65: 253-258.
13. Chrysant SG: Possible pathophysiologic mechanisms supporting the superior stroke protection of angiotensin receptor blockers compared to angiotensin-converting enzyme inhibitors: clinical and experimental evidence. J Hum Hypertens 2005; 19: 923-931.
14. Fournier A, Messerli FH, Archard JM, Fernandez L: Cerebroprotection mediated by angiotensin II: a hypothesis supported by recent randomized clinical trials. J Am Coll Cardiol 2004; 43: 1343-1347.
15. Epstein BJ, Gums JG: Can the renin-angiotensin system protect against stroke? A focus on angiotensin II receptor blockers. Pharmacotherapy 2005; 25: 531-539.
16. Bushnell CD, Johnston DCC, Goldstein LB: Retrospective assessment of initial stroke severity: comparison of the NIH Stroke Scale and the Canadian Neurological Scale. Stroke 2001; 32: 656-660.
17. Furlan A, Higashida R, Wechsler L, et al: Intra-arterial prourokinase for acute ischemic stroke. The PROACT II Study. JAMA 1999; 282: 2003-2005.
18. Sharma JC, Fletcher S, Vassallo M, Ross I: Prior aspirin therapy, subsequent stroke severity and mortality and relationship with cardiovascular risk factors in patients admitted to hospital with acute stroke. Heart Drug 2002; 2: 221-227.
19. Kolominsky-Rabas PL, Weber M, Gefeller O, Neundoerfer B, Heuschmann PU: Epidemiology of ischemic stroke subtypes according to TOAST criteria: incidence, recurrence, and long-term survival in ischemic stroke subtypes. Stroke 2001; 32: 2735-2740.
20. Vauthey C, Freitas GR, van Melle G, Devuyst G, Bogousslavsky J: Better outcome after stroke with higher serum cholesterol levels. Neurology 2000; 54: 1944-1948.
21. Olsen TS, Christensen RHB, Kammersgaard LP, Andersen KK: Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality. Stroke 2007; 38: 2646-2651.
22. Chen J, Zhang ZG, Li Y, et al: Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003; 53: 743-751.
23. Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM, FASTER investigators: Fast assessment of stroke and transient ischemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007; 6: 961-969.
24. Schwartz GG, Olsson AG, Ezekowitz MD, et al: Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes. The MIRACL study: a randomized controlled trial. JAMA 2001; 285: 1711-1718.
25. Vibo R, Kõrv J, Roose M: One-year outcome after first-ever stroke according to stroke subtype, severity, risk factors and pre-stroke treatment. Eur J Neurol 2007; 14: 435-439.
26. Redon J, Cea-Calvo L, Lozano JV, et al: Differences in blood pressure control and stroke mortality across Spain: PREV-ICTUS Study. Hypertension 2007; 49: 799-805.
27. Dai WJ, Funk A, Herdegen T, Unger T, Culman J: Blockade of central angiotensin AT 1 receptors improves neurological outcome and reduces expression of AP-1 transcription factors after focal brain ischemia in rats. Stroke 1999; 30: 2391-2399.
28. Fernandez LA, Caride VJ, Strömber C, Näveri L, Wicke JD: Angiotensin AT 2 receptor stimulation increases survival in gerbils with abrupt unilateral carotid ligation. J Cardiovasc Pharmacol 1994; 24: 937-940.
29. Sever P, Dahlof B, Poulter N, et al: Potential synergy between lipid-lowering and bloodpressure-lowering in the Anglo-Scandinavian Cardiac Outcomes Trial. Eur Heart J 2006; 27: 2982-2988.
30. Horiuchi M, Cui TX, Li Z, Li JM, Nakagami H, Iwai M: Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation. Circulation 2003; 107: 106-112.
31. Nickenig G: Should angiotensin II receptor blockers and statins be combined? Circulation 2004; 110: 1013-1020.
32. Hajat C, Hajat S, Sharma P: Effects of poststroke pyrexia on stroke outcome: a metaanalysis of studies in patients. Stroke 2000; 31: 410-414.
33. Martini SR, Kent TA: Hyperglycemia in acute ischemic stroke: a vascular perspective. J Cereb Blood Flow Metab 2007; 27: 435-451.